0000899243-22-031355.txt : 20220916
0000899243-22-031355.hdr.sgml : 20220916
20220916180107
ACCESSION NUMBER: 0000899243-22-031355
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220916
FILED AS OF DATE: 20220916
DATE AS OF CHANGE: 20220916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sokol Gerald H
CENTRAL INDEX KEY: 0001711894
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38169
FILM NUMBER: 221248988
MAIL ADDRESS:
STREET 1: 44 WALL STREET
STREET 2: 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TYME TECHNOLOGIES, INC.
CENTRAL INDEX KEY: 0001537917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453864597
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 1 PLUCKEMIN WAY - SUITE 103
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: 212-461-2315
MAIL ADDRESS:
STREET 1: 1 PLUCKEMIN WAY - SUITE 103
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL GROUP ENTERPRISES CORP.
DATE OF NAME CHANGE: 20111221
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-16
1
0001537917
TYME TECHNOLOGIES, INC.
TYME
0001711894
Sokol Gerald H
C/O TYME TECHNOLOGIES, INC.
1 PLUCKEMIN WAY - SUITE 103
BEDMINSTER
NJ
07921
1
0
0
0
Common Stock
2022-09-16
4
D
0
5865
D
0
D
Director Stock Option - Option to buy
8.75
2022-09-16
4
D
0
25000
D
2026-05-09
Common Stock
25000
0
D
Director Stock Option - Option to buy
2.90
2022-09-16
4
D
0
75000
D
2028-05-24
Common Stock
75000
0
D
Director Stock Option - Option to buy
2.33
2022-09-16
4
D
0
50000
D
2028-08-26
Common Stock
50000
0
D
Director Stock Option - Option to buy
1.18
2022-09-16
4
D
0
50000
D
2029-08-22
Common Stock
50000
0
D
Director Stock Option - Option to buy
1.22
2022-09-16
4
D
0
65000
D
2030-08-19
Common Stock
65000
0
D
Director Stock Option - Option to buy
1.10
2022-09-16
4
D
0
88000
D
2031-08-23
Common Stock
88000
0
D
Director Stock Option - Option to buy
0.31
2022-09-16
4
D
0
88000
D
2032-08-23
Common Stock
88000
0
D
Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 257 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,094 shares of Syros common stock for $199.68 per share, after giving effect to the Reverse Split.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.
By: /s/ Richard Cunningham as attorney-in-fact for Gerald H. Sokol
2022-09-16